Stock Events

Stock Events

StageZero Life Sciences 

$0.01
18
+$0+0% Tuesday 15:57

Statistics

Day High
0.01
Day Low
0.01
52W High
0.07
52W Low
0
Volume
300
Avg. Volume
0
Mkt Cap
630,018.3
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

19AugExpected
Q1 2024
Q2 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-73.95%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
522,000Revenue
-386,000Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SZLSF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap11.72B
Guardant Health offers liquid biopsy tests similar to StageZero's focus on early cancer detection, making them direct competitors in the precision oncology market.
Exact Sciences
EXAS
Mkt Cap12.25B
Exact Sciences provides non-invasive cancer screening tests, competing in the early detection space with products like Cologuard, similar to StageZero's diagnostic solutions.
Fulgent Genetics
FLGT
Mkt Cap687.17M
Fulgent Genetics offers comprehensive genetic testing, directly competing with StageZero in the field of genomics and early disease detection.
Bionano Genomics
BNGO
Mkt Cap17.42M
Bionano Genomics focuses on genomic analysis, competing with StageZero in the genomics space, particularly in the structural variation analysis for disease diagnosis.
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Pacific Biosciences provides sequencing solutions that compete with StageZero's offerings in the comprehensive genomic analysis for disease detection.
Illumina
ILMN
Mkt Cap18.99B
Illumina offers sequencing and array-based solutions for genetic analysis, competing in the genomic diagnostics space with StageZero.
Qiagen NV
QGEN
Mkt Cap10.16B
Qiagen provides sample to insight solutions including cancer diagnostics, directly competing with StageZero in the molecular diagnostics market.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Thermo Fisher Scientific offers a wide range of diagnostics and research solutions, including cancer diagnostics, competing across several areas with StageZero.
Quest Diagnostics
DGX
Mkt Cap19.57B
Quest Diagnostics offers diagnostic testing services, including for cancer, competing with StageZero in the broader diagnostics and laboratory testing market.

About

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.
Show more...
CEO
Mr. James R. Howard-Tripp
Employees
40
Country
CA
ISIN
CA8525403017

Listings

OTC Link
US
SZLSF

0 Comments

Share your thoughts

FAQ

What is StageZero Life Sciences stock price today?▼
The current price of SZLSF is $0.01 USD — it has increased by +0% in the past 24 hours. Watch StageZero Life Sciences stock price performance more closely on the chart.
What is StageZero Life Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange StageZero Life Sciences stocks are traded under the ticker SZLSF.
Is StageZero Life Sciences stock price growing?▼
SZLSF stock has risen by +0% compared to the previous week, the month change is a +920% rise, over the last year StageZero Life Sciences has showed a +70% increase.
What is StageZero Life Sciences market cap?▼
Today StageZero Life Sciences has the market capitalization of 630,018.3
What is StageZero Life Sciences revenue for the last year?▼
StageZero Life Sciences revenue for the last year amounts to 522,000 USD.
What is StageZero Life Sciences net income for the last year?▼
SZLSF net income for the last year is -386,000 USD.
How many employees does StageZero Life Sciences have?▼
As of April 01, 2026, the company has 40 employees.
In which sector is StageZero Life Sciences located?▼
StageZero Life Sciences operates in the Health Care sector.
When did StageZero Life Sciences complete a stock split?▼
The last stock split for StageZero Life Sciences was on September 18, 2020 with a ratio of 1:8.
Where is StageZero Life Sciences headquartered?▼
StageZero Life Sciences is headquartered in Richmond Hill, CA.